ELSALYS BIOTECH Business Summary
The company has a portfolio of 5 programs in the development phase, including LEUKOTAC® (Inolimomab), an immunotherapy antibody demonstrating a clinical benefit in Phase 3 of a rare disease with a very poor prognosis: acute steroid resistant reaction of the graft against the host.
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Martine Brandt
FOU | Founder | - | 01/13/01 |
Thierry Menguy
FOU | Founder | - | 01/13/01 |
Vanessa Duong
FOU | Founder | - | 01/13/01 |
| Founder | - | 01/13/01 | |
Mizrahi Jacques
CTO | Chief Tech/Sci/R&D Officer | 70 | 01/14/01 |
Eric Quéméneur
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
David Liens
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/17/01 |
| Corporate Officer/Principal | - | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 01/13/01 | |
Eric Quéméneur
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Mizrahi Jacques
CTO | Chief Tech/Sci/R&D Officer | 70 | 01/14/01 |
Company contact information
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| +31.06% | 68TCr | |
| +30.35% | 59TCr | |
| -3.42% | 36TCr | |
| +18.02% | 33TCr | |
| +4.27% | 28TCr | |
| +15.53% | 24TCr | |
| +10.16% | 21TCr | |
| -8.14% | 20TCr | |
| +8.12% | 17TCr |
